Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459612 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03459612 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 68 participants.
The verdict
NCT03459612, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge.
Interventions
- DRUG Placebo
- DRUG Diphenhydramine
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-03-26 |
| Est. Completion | 2018-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459612
The ClinicalTrials.gov registry entry for NCT03459612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03459612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459612 about?
NCT03459612 is a clinical study titled "A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants". The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research ...
What is the current status of trial NCT03459612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2018-03-26. Estimated completion is 2018-06-23.
What interventions are being tested in trial NCT03459612?
The interventions under investigation include: Placebo (DRUG), Diphenhydramine (DRUG), Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03459612?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.